An interventional study of Transcranial low intensity focused ultrasound (FUS) and transcranial electrical stimulation in Closed-loop Brain Stimulation, sponsored by University of Nottingham. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by University of Nottingham · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this study is to establish if non-invasive closed-loop neuromodulation is an effective approach to enhance cognitive function in healthy 18-40 years old volunteers. The main questions it aims to answer are:
Researchers will compare different closed-loop options to their open-loop counterpart to see if closed-loop approaches can increase efficacy and reduce the variability of the stimulation compared to open-loop approaches.
Participants will:
Closed-loop approaches may offer greater efficacy and lower variability across individuals compared to current open-loop stimulation approaches, yet they remain a relatively new approach, with no studies evaluating closed-loop transcranial low-intensity focused ultrasound stimulation (FUS) yet.
For this reason, we will collect and evaluate cognitive, biological and metabolic data from healthy participants, before and after closed-loop and open-loop stimulation interventions. This will allow us to compare our proposed closed-loop stimulation approach to stablished non-invasive techniques and to investigate the underlying mechanisms through which FUS can alter brain activity.
For this study, participants will attend multiple visits. To assess eligibility, participants will attend one initial session in-person before the start of the study.
Following safety guidelines, each participant will receive a maximum of two 1-hour MRI scanning sessions in a single week.
This study will be separated into two blocks of stimulation sessions: one block for tACS-FUS, and another block for TI-FUS. Participants will be randomly allocated to receive one of the blocks.
Before the during recruitment, participants will be asked to complete online some baseline questionnaires such as the O-Life inventory, BECK, MAIA, or STAI. Furthermore, full eligibility will be assessed in person.
At the first appointment, participants will have a brain scan at Sir Peter Mansfield Imaging Centre or Queen's Medical Centre, Nottingham, UK. This will help us to apply the brain stimulation to the right part of the participant's brain, as well as obtain baseline functional, metabolic and structural information.
Participants will be randomly allocated to either receive open-loop FUS (FUS with Sham tES), closed-loop FUS (dual FUS-tES), tES with Sham FUS, or double sham FUS-tES, in the second appointment and the other interventions in the subsequent visits for their assigned block. During all stimulation sessions, we will use an AntNeuro neuronavigation system to guide the location of the transducer.
During either of the stimulation visits, participants will have physiological (EEG) and cognitive markers recorded. Some emotional assessments (i.e., through a short STAI) will be performed before and after stimulation. EEG recordings will be conducted before, during and after stimulation on the same day. Rest-state EEG will be recorded pre-stimulation before the start of the cognitive tasks, and post-stimulation after the end of the cognitive tasks.
The participant will then undergo one cognitive assessment, which will consists on a visual working memory task (delayed-spatial-estimation-task). The task involves visual stimuli, with responses recorded via keyboard. The task is designed to take approximately 5-15 minutes to complete on pre and post-stimulation. The duration of the task during stimulation will be adapted to the duration of the stimulation. Following this, participants will receive the allocated intervention.
Participants will have the same physiological and cognitive assessments recorded during the stimulation and after the stimulation has been completed. For the closed-loop stimulation, participants will also undergo an MRI scanning after the stimulation.
The first visit, consisting of brain scan, will be separated by at least 24 hours from the second visit. Subsequent visits will be separated by at least one week from each other.
During each consecutive appointment, participants will be asked about any changes to their eligibility and continued consent.
University of Nottingham is the lead sponsor of 465 studies on the registry; 80 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Transcranial low intensity focused ultrasound stimulation (FUS) with 500kHz transducer for following either the continuous theta burst or intermittent theta burst protocol using the NeuroFus PRO system
Other: Transcranial low intensity focused ultrasound (FUS) · Procedure: Magnetic Resonance Imaging
Closed-loop Transcranial Electrical Stimulation by means of tACS or TI delivered through a Digitimer DS5 for brain entrainment phase-locked on peak or trough to transcranial low intensity FUS delivered to dACC through the NeuroFUS PRO system
Other: Transcranial low intensity focused ultrasound (FUS) · Other: transcranial electrical stimulation · Procedure: Magnetic Resonance Imaging
tACS or TI delivered through a Digitimer DS5 for brain entrainment phase-locked on peak or trough
Other: transcranial electrical stimulation · Procedure: Magnetic Resonance Imaging
FUS delivered to ventricles or FUS and tACS located on head, one of them on or off depending on sham, or active.
Other: Transcranial low intensity focused ultrasound (FUS) · Procedure: Magnetic Resonance Imaging
Low intensity focused ultrasound stimulation (FUS) with 500kHz transducer for following either the continuous theta burst or intermittent theta burst protocol using the NeuroFus PRO system
Also known as: LIFU, tFUS, TUS
Transcranial electrical stimulation (by means of transcranial alternating current stimulation (tACS) or non-invasive temporal interference (TI) electrical stimulation) using the DS5 isolated bipolar constant current stimulator together connected to a wave generator and with two electrodes for tACS (TI implementation will be carried out with two DS5 systems, separate wave generators and four electrodes).
Also known as: tES
We obtain baseline functional, metabolic and structural information through MRI and MRS scanning
Also known as: MRI
Change from Baseline in EEG Power in Alpha Band (8-12Hz)
Time frame: Baseline to 10 weeks, measured immediately before, during, and immediately after stimulation
Change from Baseline in EEG Power in Theta Band (4-7Hz)
Time frame: Baseline to 10 weeks, measured immediately before, during, and immediately after stimulation
Change from Baseline in EEG Power in Beta Band (13-30Hz)
Time frame: Baseline to 10 weeks, measured immediately before, during, and immediately after stimulation
Change from Baseline in EEG Power in Gamma Band (31-45Hz)
Time frame: Baseline to 10 weeks, measured immediately before, during, and immediately after stimulation
Changes from Baseline in EEG-derived spectral power
Time frame: Baseline to 10 weeks, measured immediately before, during, and immediately after stimulation
Changes from Baseline in Functional connectivity (e.g., through changes in Phase-locked value (PLV))
Time frame: Baseline to 10 weeks, measured immediately before, during, and immediately after stimulation
Average Reaction time (ms) measured from the Visual Working memory task
Time frame: Baseline to 10 weeks, measured immediately before, during, and immediately after stimulation
Average Overall accuracy (%) measured from Visual Working Memory task
Time frame: Baseline to 10 weeks, measured immediately before, during, and immediately after stimulation
Change from Baseline in Target-Region metabolite Concentration measured via Magnetic Resonance Spectroscopy (MRS)
Time frame: Baseline (Day 1) to immediately after closed-loop post-stimulation intervention
Changes from Baseline in Functional Connectivity calculated from functional Magnetic Resonance Imaging (fMRI)
Time frame: Baseline (Day 1) to immediately after closed-loop post-stimulation intervention
Changes from Baseline on Structural connectivity metrics derived from multi-shell diffusion MRI (dMRI) tractography
Time frame: Baseline (Day 1) to immediately after closed-loop post-stimulation intervention
Structured questionnaire assessing adverse effects of the intervention
Time frame: Immediately after stimulation, 24 hours after stimulation and 1 week after stimulation
Plan to share: Undecided
Start is estimated for Nov 2026; primary completion for Aug 2027, 9 months later.
Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, on Nov 16, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.